Laboratoires KÔL (KÔL)
KÔL will contribute to writing and reviewing protocols for preclinical and clinical studies, provide Olisens® materials, and support the evaluation of the potential of novel therapeutic drugs in preclinical models for the 7 REDs. It will also take a lead role in regulatory affairs, including obtaining orphan drug designation for the targeted therapeutic indications.
KÔL’s product, Olisens®, is an oligonucleotide antisense for the treatment of corneal neovascularization, studied in 4 preclinical REDs models:
- CN: Corneal Vascularization;
- AAK – Associated Aniridia Keratopathy;
- OGVHG – Ocular Graft Versus Host Diseases;
- LSCD – Limbal Stem Cell Deficiency.
Furthermore, Olisens® will undergo a pilot prospective randomized clinical trial to prevent exacerbation of corneal neovascularization in Aniridia-Associated Keratopathy. KÔL will also provide expertise for the development of industrial formulations for the other 8 products.